Gilenya News and Research

RSS
S1P1R variation may cause differential patient responses to fingolimod treatment

S1P1R variation may cause differential patient responses to fingolimod treatment

Added benefit of multiple sclerosis drug fingolimod not proven, says IQWiG

Added benefit of multiple sclerosis drug fingolimod not proven, says IQWiG

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

Novartis launches ‘24 Life Hacks in 24 hours’ showing commitment to help people with MS access guidance and advice

New study shows 'alarming rise' in costs of MS drugs over last 20 years

New study shows 'alarming rise' in costs of MS drugs over last 20 years

SLU researchers discover pain pathway and potential way to block it

SLU researchers discover pain pathway and potential way to block it

Study offers new insight into benefits of vitamin D in people with multiple sclerosis

Study offers new insight into benefits of vitamin D in people with multiple sclerosis

ALS TDI forms research partnership with Neurimmune to advance potential treatments for ALS

ALS TDI forms research partnership with Neurimmune to advance potential treatments for ALS

Multiple sclerosis patients see "rapid expansion" of effective new treatment options

Multiple sclerosis patients see "rapid expansion" of effective new treatment options

New strategy will have positive impact on people with brain disorders

New strategy will have positive impact on people with brain disorders

Fingolimod offers minor added benefit for patients with RRMS

Fingolimod offers minor added benefit for patients with RRMS

AB Science announces results from masitinib phase 2 study on MS

AB Science announces results from masitinib phase 2 study on MS

Gilenya - pill for relapsing-remitting multiple sclerosis recommended by NICE

Gilenya - pill for relapsing-remitting multiple sclerosis recommended by NICE

Gilenya prevents and reverses symptoms of ventricular hypertrophy

Gilenya prevents and reverses symptoms of ventricular hypertrophy

Multiple sclerosis drug Gilenya under investigation by FDA and EMA

Multiple sclerosis drug Gilenya under investigation by FDA and EMA

Phase III study of BG-12 in relapsing-remitting multiple sclerosis sparks excitement

Phase III study of BG-12 in relapsing-remitting multiple sclerosis sparks excitement

New report on the immunomodulators market outlook to 2016

New report on the immunomodulators market outlook to 2016

Decision Resources: 63% of neurologists select Tysabri as effective MS treatment

Decision Resources: 63% of neurologists select Tysabri as effective MS treatment

Pharmacy costs for multiple sclerosis patients increase at a faster rate than medical costs

Pharmacy costs for multiple sclerosis patients increase at a faster rate than medical costs

Gilenya can reduce risk of disability progression in patients with RRMS

Gilenya can reduce risk of disability progression in patients with RRMS

Novartis new MS treatment receives Notice of Compliance in Canada

Novartis new MS treatment receives Notice of Compliance in Canada